卡泊芬净与两性霉素B对曲霉属和镰刀菌属的体外协同作用
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.
作者信息
Arikan Sevtap, Lozano-Chiu Mario, Paetznick Victor, Rex John H
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 77030, USA.
出版信息
Antimicrob Agents Chemother. 2002 Jan;46(1):245-7. doi: 10.1128/AAC.46.1.245-247.2002.
Abstract
We investigated the in vitro interaction of caspofungin and amphotericin B for clinical isolates of Aspergillus and FUSARIUM: Synergy tests were performed using the checkerboard method and following the NCCLS M38-P guidelines in Antibiotic Medium 3 broth supplemented to 2% glucose. Antagonism was not observed for any of the isolates tested. Caspofungin and amphotericin B were synergistic or synergistic to additive for at least half of the isolates.
摘要
我们研究了卡泊芬净和两性霉素B对烟曲霉和镰刀菌临床分离株的体外相互作用：采用棋盘法并遵循NCCLS M38-P指南，在添加2%葡萄糖的抗生素培养基3肉汤中进行协同试验。在所测试的任何分离株中均未观察到拮抗作用。卡泊芬净和两性霉素B对至少一半的分离株具有协同作用或协同至相加作用。
相似文献
1
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.
Antimicrob Agents Chemother. 2002 Jan;46(1):245-7. doi: 10.1128/AAC.46.1.245-247.2002.
2
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Antimicrob Agents Chemother. 2005 Aug;49(8):3572-4. doi: 10.1128/AAC.49.8.3572-3574.2005.
3
In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points.
Antimicrob Agents Chemother. 2003 Apr;47(4):1416-8. doi: 10.1128/AAC.47.4.1416-1418.2003.
4
Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
J Antimicrob Chemother. 2006 Dec;58(6):1168-76. doi: 10.1093/jac/dkl392. Epub 2006 Oct 27.
5
In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp.
Antimicrob Agents Chemother. 2004 Sep;48(9):3279-83. doi: 10.1128/AAC.48.9.3279-3283.2004.
6
Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates.
Antimicrob Agents Chemother. 2002 Sep;46(9):3084-7. doi: 10.1128/AAC.46.9.3084-3087.2002.
7
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Diagn Microbiol Infect Dis. 2003 Feb;45(2):131-5. doi: 10.1016/s0732-8893(02)00507-2.
8
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.
Antimicrob Agents Chemother. 2001 Jan;45(1):327-30. doi: 10.1128/AAC.45.1.327-330.2001.
9
Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro.
Antimicrob Agents Chemother. 2012 Dec;56(12):6414-6. doi: 10.1128/AAC.00687-12. Epub 2012 Oct 1.
10
Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.
J Clin Microbiol. 2005 Aug;43(8):3788-92. doi: 10.1128/JCM.43.8.3788-3792.2005.
引用本文的文献
1
Challenging fungal infections in cystic fibrosis: a case of mixed Aspergillus species infection and antifungal combination testing.
Access Microbiol. 2024 Apr 19;6(4). doi: 10.1099/acmi.0.000758.v3. eCollection 2024.
2
Application of antimicrobial peptides in plant protection: making use of the overlooked merits.
Front Plant Sci. 2023 Jul 19;14:1139539. doi: 10.3389/fpls.2023.1139539. eCollection 2023.
3
Non- mould lung infections.
Eur Respir Rev. 2022 Oct 19;31(166). doi: 10.1183/16000617.0104-2022. Print 2022 Dec 31.
4
Efficacy and Safety of Combination Antifungals as Empirical, Preemptive, and Targeted Therapies for Invasive Fungal Infections in Intensive-Care Units.
Infect Drug Resist. 2022 Sep 9;15:5331-5344. doi: 10.2147/IDR.S381851. eCollection 2022.
5
The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections.
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0038022. doi: 10.1128/aac.00380-22. Epub 2022 Jun 7.
6
Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients.
J Fungi (Basel). 2022 Apr 17;8(4):415. doi: 10.3390/jof8040415.
7
Aspergillus tubingensis Endocarditis: A Case Report and Review of the Literature.
Mycopathologia. 2022 Jun;187(2-3):249-258. doi: 10.1007/s11046-022-00621-0. Epub 2022 Mar 10.
8
Effect of Cold Atmospheric Plasma Jet Associated to Polyene Antifungals on Biofilms.
Molecules. 2021 Sep 25;26(19):5815. doi: 10.3390/molecules26195815.
9
A network representation approach for COVID-19 drug recommendation.
Methods. 2022 Feb;198:3-10. doi: 10.1016/j.ymeth.2021.09.009. Epub 2021 Sep 23.
10
Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19.
Clin Microbiol Infect. 2020 Nov;26(11):1582-1584. doi: 10.1016/j.cmi.2020.06.026. Epub 2020 Jun 30.
本文引用的文献
1
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.
Antimicrob Agents Chemother. 2001 Jan;45(1):327-30. doi: 10.1128/AAC.45.1.327-330.2001.
2
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.
Antimicrob Agents Chemother. 2000 Sep;44(9):2310-8. doi: 10.1128/AAC.44.9.2310-2318.2000.
3
Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.
Antimicrob Agents Chemother. 2000 Aug;44(8):2081-5. doi: 10.1128/AAC.44.8.2081-2085.2000.
4
Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
J Clin Microbiol. 1999 Dec;37(12):3946-51. doi: 10.1128/JCM.37.12.3946-3951.1999.
5
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.
Antimicrob Agents Chemother. 1998 Jan;42(1):129-34. doi: 10.1128/AAC.42.1.129.
6
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
Antimicrob Agents Chemother. 1997 Nov;41(11):2333-8. doi: 10.1128/AAC.41.11.2333.
7
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Antimicrob Agents Chemother. 1997 Feb;41(2):331-6. doi: 10.1128/AAC.41.2.331.
8
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.
Antimicrob Agents Chemother. 1994 Jul;38(7):1480-9. doi: 10.1128/AAC.38.7.1480.
9
Detection of amphotericin B-resistant Candida isolates in a broth-based system.
Antimicrob Agents Chemother. 1995 Apr;39(4):906-9. doi: 10.1128/AAC.39.4.906.
Zotero 插件